Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr;26(4):e704-e709.
doi: 10.1002/onco.13645. Epub 2021 Jan 11.

Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer

Daniel D Von Hoff  1 , Derek Cridebring  1 , Olivia Yu Tian  2 , Haiyong Han  1 , Rafia Bhore  2 , Twyla Franco  2 , Michael S Ondovik  2 , Chrystal U Louis  2
Affiliations
Clinical Trial

Analysis of the Role of Plasma 25-Hydroxyvitamin D Levels in Survival Outcomes in Patients from the Phase III MPACT Trial of Metastatic Pancreatic Cancer

Daniel D Von Hoff et al. Oncologist. 2021 Apr.

Abstract

Background: We examined overall survival (OS) outcomes based on plasma 25-hydroxyvitamin D [25(OH)D] levels in this post hoc analysis of the phase III MPACT trial of metastatic pancreatic cancer.

Materials and methods: Patients were subdivided based on 25(OH)D level: sufficient (≥30 ng/mL), relatively insufficient (20-<30 ng/mL), or insufficient (<20 ng/mL).

Results: Of 861 patients randomized in MPACT, 422 were included in this analysis. In the all-patients group, the median OS among those with insufficient, relatively insufficient, and sufficient 25(OH)D levels was 7.9, 9.4, and 7.8 months, respectively. No statistically significant OS difference was observed with relatively insufficient (p = .227) or sufficient (p = .740) versus insufficient 25(OH)D levels or with sufficient vs relatively insufficient (p = .301) 25(OH)D levels.

Conclusion: No association was observed between plasma 25(OH)D levels and survival. Further investigations are needed to understand any role of vitamin D in pancreatic cancer. Clinical trial identification number. NCT00844649.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1
Figure 1
Kaplan‐Meier curves for overall survival in (A) all patients, (B) patients treated with nab‐paclitaxel plus gemcitabine, and (C) patients treated with gemcitabine alone (intent‐to‐treat population).Abbreviation: CI, confidence interval.
See this image and copyright information in PMC

Comment in

References

    1. National Comprehensive Cancer Network . Pancreatic Adenocarcinoma (Version 1.2021). Available at https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed Dec 29, 2020.
    1. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317–327. - PMC - PubMed
    1. Le DT, Uram JN, Wang H et al. PD‐1 blockade in tumors with mismatch‐repair deficiency. N Engl J Med 2015;372:2509–2520. - PMC - PubMed
    1. Yuan C, Qian ZR, Babic A et al. Prediagnostic plasma 25‐hydroxyvitamin D and pancreatic cancer survival. J Clin Oncol 2016;34:2899–2905. - PMC - PubMed
    1. Zhang X, Huang XZ, Chen WJ et al. Plasma 25‐hydroxyvitamin D levels, vitamin D intake, and pancreatic cancer risk or mortality: A meta‐analysis. Oncotarget 2017;8:64395–64406. - PMC - PubMed

Publication types

MeSH terms

Associated data